Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Neoplasm Female × Anastrozole × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 92 Carcinoma, Intraductal, Noninfiltrating 6 Neoplasm Metastasis 3 Breast Neoplasms, Male 3 Breast Carcinoma In Situ 3 Triple Negative Breast Neoplasms 2 Ovarian Neoplasms 2 Neoplasms 2 Endometrial Neoplasms 2 Breast Cancer Metastatic 2 Sexual Dysfunction, Physiological 1 Seizures 1 Multiple Endocrine Neoplasia Type 1 1 Locoregional Recurrence 1 Lethal Congenital Contracture Syndrome 2 1 Inflammatory Breast Neoplasms 1 Hypogonadism 1 Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer 1 HER2-positive Breast Cancer 1 HER2 Negative Breast Cancer 1 Granulosa Cell Ovarian Cancer 1 Fallopian Tube Neoplasms 1 Erectile Dysfunction 1 Epilepsy 1 ER+ Breast Cancer 1 Carcinoma, Non-Small-Cell Lung 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Neoplasm Female 1 Breast Diseases 1 Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

pertuzumab 1 penpulimab 1 dalpiciclib 1 anlotinib 1 Tretinoin 1 Trastuzumab 1 Fulvestrant 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04113863 2025-12-18

ATRA

Mario Negri Institute for Pharmacological Research

Phase 2 Terminated

Breast Neoplasm Female

Data powered by HemOnc (CC BY 4.0) Colophon ⚡